AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8435379
Drug: Torasemide 100
RxNorm normalized name: Torasemide 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 100 mg intravenous dose in patients with moderate renal insufficiency
Trial: 8435379
Drug: Torasemide 200
RxNorm normalized name: torsemide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 200 mg intravenous dose in patients with severe renal insufficiency
Trial: 8435379
Drug: Torasemide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (various doses)
Trial: 24497599
Drug: Polyhexanide solution
RxNorm normalized name: Polyhexanide
DrugBank: Polihexanide (DB12277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyhexanide solution
Trial: 18374544
Drug: Aripiprazole (ARI)
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole (ARI) 10-30 mg/day
Trial: 12814905
Drug: Ondansetron treatment
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron treatment (1, 4, and 16 micro g/kg twice daily)
Trial: 24984823
Drug: Magnesium supplements
RxNorm normalized name: Magnesium supplements, alimentary tract and metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplements (8.1mmol of magnesium-pidolate, administered twice a day)
Trial: 11815760
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (1 mg/kg, 1 dose)
Trial: 6161451
Drug: Solcoseryl gel
RxNorm normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solcoseryl gel
Trial: 6353619
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal spray (200 micrograms, twice daily for 4 weeks)
Trial: 22579722
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid tablet (∼1,000 μg)
Trial: 22579722
Drug: Multivitamin softgel
RxNorm normalized name: Complete Formulation Multivitamin Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin softgel capsule (∼1,000 μg)
Trial: 16163525
Drug: Alcohol (0.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.65 g/kg) after prior task experience with visual degradation
Trial: 10545590
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (2 x 10^10 colony-forming units in capsules given twice daily during antimicrobial treatment)
Trial: 7570411
Drug: Cotrimoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (960 mg twice daily)
Trial: 7570411
Drug: Amoxicillin, Cotrimoxazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, Cotrimoxazole, or Placebo with oral corticosteroids
Trial: 7570411
Drug: Amoxicillin, Cotrimoxazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, Cotrimoxazole, or Placebo
Trial: 6985560
Drug: bezafibrate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (3 x 200 mg/d for 8 weeks)
Trial: 6985560
Drug: clofibrate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clofibrate (3 x 500 mg/d for 8 weeks)
Trial: 21173180
Drug: Miconazole oral
RxNorm normalized name: miconazole Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole oral gel (85 mg thrice daily)
Trial: 19025522
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml (18 mg) hypobaric 0.6% lidocaine
Trial: 19025522
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml (24 mg) hypobaric 0.6% lidocaine
Trial: 23766519
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol (D₃) 600,000 IU
Trial: 23766519
Drug: Oral ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ergocalciferol (D₂) 600,000 IU
Trial: 23766519
Drug: Intramuscular cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular cholecalciferol (D₃) 600,000 IU
Trial: 23766519
Drug: Intramuscular ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ergocalciferol (D₂) 600,000 IU
Trial: 18405151
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (routine western methods including dehydration, brain-protection, anti-platelet agglutination, improving circulation, and expectant treatment)
Trial: 11590492
Drug: Treatment 3
RxNorm normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3 (didanosine, indinavir, and HU 500-1,000 mg/day)
Trial: 11590492
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (two nucleosides plus a protease inhibitor)
Trial: 10868720
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2
Trial: 1534642
Drug: Sustained-release nicardipine
RxNorm normalized name: nicardipine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nicardipine
Trial: 31449090
Drug: Enhanced testing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced testing, linkage to care, and ARV treatment in 15 intervention villages.
Trial: 26632428
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg melatonin (Melaxen(TM)) daily at 22:30 h for two weeks
Trial: 24958736
Drug: UFT/LV (UFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (UFT 300 mg m(‐2) day(‐1), LV 75 mg/day on days 1-28 every 5 weeks)
Trial: 24958736
Drug: 5‐FU/l‐LV (5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/l‐LV (5‐FU 500 mg/m(2), l‐LV 250 mg/m(2) on days 1, 8, 15, 22, 29, 36 every 8 weeks)
Trial: 24958736
Drug: 5‐FU/l‐LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/l‐LV
Trial: 17825800
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75-300 mg/day)
Trial: 11488362
Drug: Fluoxetine (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-60 mg/day)
Trial: 17825800
Drug: Fluoxetine (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (continuation phase)
Trial: 16362597
Drug: Terazosin 10
RxNorm normalized name: terazosin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 10 mg after one month for group 2 and those with improvement or ineffectiveness from 5 mg
Trial: 10080319
Drug: Implant-tissue-supported mandibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-tissue-supported mandibular overdenture on two IMZ implants (IMZ)
Trial: 1539851
Drug: Heparin 200
RxNorm normalized name: HEPARIN 2000 UNIT/ML LOCK FLUSH SYR 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 200 U/kg and additional heparin as needed to maintain ACT > 400 s (group A, n = 30)
Trial: 1539851
Drug: Heparin 400
RxNorm normalized name: heparin 40000 units/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 400 U/kg and additional heparin as needed to maintain whole blood heparin concentration > 4.0 U/ml (group H, n = 33)
Trial: 27098551
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (PO-D)
Trial: 27098551
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (IV-D)
Trial: 20218793
Drug: Usual starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Usual starting dose of SSRIs (10 mg escitalopram; 20 mg fluoxetine, paroxetine, citalopram; 50 mg sertraline and fluvoxamine)
Trial: 20218793
Drug: Higher starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher starting doses of SSRIs
Trial: 20218793
Drug: Usual starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Usual starting dose of SSRIs
Trial: 18767581
Drug: Turtle probing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Turtle probing the cave needling method (acupuncture therapy), treated once a day for two weeks.
Trial: 18767581
Drug: Motilium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motilium (10 mg oral administration, thrice daily, 30 minutes before meals, for two weeks).
Trial: 15982149
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (present-centered therapy; PCT)
Trial: 9737828
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lubeluzole
Trial: 9737828
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lubeluzole
Trial: 9737828
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lubeluzole
Trial: 9737828
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of lubeluzole (5, 10, 15 mg)
Trial: 9737828
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of lubeluzole
Trial: 30312163
Drug: Complementary Spiritist
RxNorm normalized name: TURPENTINE SPIRITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary Spiritist Therapy (3 days, 10 mins per day/session) alongside conventional treatment
Trial: 27616732
Drug: 7% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% maltodextrin solution (CHO)
Trial: 27616732
Drug: 14% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14% maltodextrin solution (CHO)
Trial: 24103519
Drug: Oleaginous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleaginous extract of kale (50 mL providing 10 mg lutein and 3 mg zeaxanthin per day)
Trial: 14519051
Drug: Diuretics and
RxNorm normalized name: Low-ceiling diuretics and potassium-sparing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics and calcium-channel blockers
Trial: 29097499
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose lenalidomide (n=15)
Trial: 29097499
Drug: Sequential azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential azacitidine and lenalidomide (n=39)
Trial: 27655756
Drug: Low egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low egg (LE) - 75 g cooked egg
Trial: 20799930
Drug: Group Art
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Art Therapy plus standard care
Trial: 12480610
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 microg twice a day plus montelukast 10 mg at night for 8 weeks
Trial: 10585054
Drug: Heparin‐bonded circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐bonded circuit with no albumin preprime
Trial: 10585054
Drug: Heparin‐bonded circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐bonded circuit with albumin preprime
Trial: 30759035
Drug: Aspirin 20
RxNorm normalized name: aspirin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 20 mg BD (12-hourly)
Trial: 21226576
Drug: Amoxicillin‐clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanate
Trial: 18642636
Drug: Median Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median Nerve Stimulation (MNS) therapy
Trial: 13679496
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks (Group A)
Trial: 13679496
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg daily for 8 weeks (Group B)
Trial: 10735395
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg twice per day for 7 days (n = 128)
Trial: 10735395
Drug: Trimethoprim-sulfamethoxazole, 160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (n = 127)
Trial: 1420504
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LDAC) 10 mg/m2 subcutaneously BID
Trial: 28145050
Drug: CYP2B6 516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2B6 516 G/G genotype
Trial: 16505299
Drug: Defined over-ground
RxNorm normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defined over-ground mobility therapy (CONT)
Trial: 16505299
Drug: Body weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight support on a treadmill (BWSTT) and Defined over-ground mobility therapy (CONT)
Trial: 12620436
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (newly initiated estrogen patch)
Trial: 12620436
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal estrogen therapy
Trial: 10710064
Drug: Ferumoxil (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxil (900 ml)
Trial: 1540019
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil (10 ml daily)
Trial: 3457524
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg four times daily)
Trial: 18625629
Drug: COBRA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA treatment comprising sulfasalazine, methotrexate and high‐dose step‐down prednisolone, intensified by adding hydroxychloroquine and continued low‐dose prednisolone
Trial: 12679450
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone (up to 45 mg for 77% of patients)
Trial: 12679450
Drug: 850 mg
RxNorm normalized name: bran 850 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 850 mg metformin (up to 2550 mg for 73% of patients)
Trial: 12679450
Drug: 850 mg
RxNorm normalized name: bran 850 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 850 mg metformin
Trial: 8770436
Drug: Self-care manual
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care manual (part of the sequential treatment).
Trial: 1593057
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg twice daily for 6 months
Trial: 6323667
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment) applied four times a day for 7 days
Trial: 6323667
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment)
Trial: 31420274
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid levels in the 3rd tertile (≥327 μmol/L)
Trial: 31420274
Drug: High uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High uric acid levels (≥327 μmol/L)
Trial: 27734491
Drug: Humidified oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth open
Trial: 27734491
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask oxygenation at 10 l.min‐1
Trial: 27734491
Drug: Humidified oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth closed
Trial: 24670704
Drug: Treatment-induced decrease
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-induced decrease in CXCL10 levels in patients with 'insufficient' and 'deficient' vitamin D levels.
Trial: 12014907
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antibiotic prophylaxis)
Trial: 30883233
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical agent
Trial: 29156909
Drug: Palliative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiotherapy (RT) with a single 8 Gy dose
Trial: 25428176
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 0.5% (4 drops daily)
Trial: 17578316
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SFI) in cooperation with chemotherapy (CAF protocol)
Trial: 17578316
Drug: Chemotherapy (CAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CAF protocol) alone
Trial: 10874
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate feedback during treatment
Trial: 21114478
Drug: Isotretinoin at
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 24 weeks (group A)
Trial: 21114478
Drug: Isotretinoin at
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily for 24 weeks (group B)
Trial: 21114478
Drug: Isotretinoin at
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks for 6 weeks (group C)
Trial: 21114478
Drug: Isotretinoin at
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily (group B)
Trial: 21114478
Drug: Isotretinoin at
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily (group A)
Trial: 21114478
Drug: Isotretinoin at
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks (group C)
Trial: 21114478
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment (group B)
Trial: 21114478
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (group C)
Trial: 16326295
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group (2.5 g magnesium sulphate infusion intraoperatively over 30 minutes)
Trial: 16326295
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (normal saline solution)
Trial: 11119180
Drug: Cue-dose training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue-dose training (CD)
Trial: 8327595
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.035 IU/kg body weight)
Trial: 29534874
Drug: VT‐1161 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Trial: 29534874
Drug: VT‐1161 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Trial: 29534874
Drug: VT‐1161 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 23 weeks
Trial: 29534874
Drug: VT‐1161 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 23 weeks
Trial: 27234671
Drug: Once-weekly teriparatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly teriparatide therapy for 72 weeks